Effects on food intake and blood lipids of cannabinoid receptor 1 antagonist treatment in lean rats

Obesity

Volumn 16, Issue 11, 2008, Pages 2451-2455

  Bennetzen, Marianne F ^a   Nielsen, Maria P ^a   Richelsen, Bjørn ^b   Pedersen, Steen B ^b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; CANNABINOID 1 RECEPTOR; CHOLESTEROL; FATTY ACID; GLYCEROL; LIPID; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE; RIMONABANT; TRIACYLGLYCEROL;

ANIMAL; ARTICLE; BLOOD; BODY WEIGHT; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; EATING; MALE; PATHOPHYSIOLOGY; PHYSIOLOGY; RAT; WISTAR RAT;

ADIPONECTIN; ANIMALS; BODY WEIGHT; CHOLESTEROL; DISEASE MODELS, ANIMAL; EATING; FATTY ACIDS, NONESTERIFIED; GLYCEROL; LIPIDS; MALE; PIPERIDINES; PYRAZOLES; RATS; RATS, WISTAR; RECEPTOR, CANNABINOID, CB1; THINNESS; TRIGLYCERIDES;

RATTUS;

EID: 55249084159     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1038/oby.2008.390     Document Type: Article

References (16)

1. Di Marzo V, Matias I. Endocannabinoid control of food intake and energy balance. Nat Neurosci 2005;8:585-589.
2. Boyd ST. The endocannabinoid system. Pharmacotherapy 2006;26:S218-S221.
3. Colombo G, Agabio R, Diaz G et al. Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. Life Sci 1998;63:L113-L117.
4. Pagotto U, Pasquali R. The role of the endocannabinoid pathway in metabolism and diabetes. Curr Opin Endocrinol Diabetes 2006;13:171-178.
5. Gessa GL, Orru A, Lai P et al. Lack of tolerance to the suppressing effect of rimonabant on chocolate intake in rats. Psychopharmacology (Berl) 2006;185:248-254.
6. Jbilo O, Ravinet-Trillou C, Arnone M et al. The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance. FASEB J 2005;19:1567-1569.
7. Despres JP, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005;353:2121-2134.
8. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005;365:1389-1397.
9. Thornton-Jones ZD, Kennett GA, Benwell KR et al. The cannabinoid CB1 receptor inverse agonist, rimonabant, modifies body weight and adiponectin function in diet-induced obese rats as a consequence of reduced food intake. Pharmacol Biochem Behav 2006;84:353-359.
10. Diehl KH, Hull R, Morton D et al. A good practice guide to the administration of substances and removal of blood, including routes and volumes. J Appl Toxicol 2001;21:15-23.
11. Tsutsumi K, Hagi A, Inoue Y. The relationship between plasma high density lipoprotein cholesterol levels and cholesteryl ester transfer protein activity in six species of healthy experimental animals. Biol Pharm Bull 2001;24:579-581.
12. Vickers SP, Webster LJ, Wyatt A, Dourish CT, Kennett GA. Preferential effects of the cannabinoid CB1 receptor antagonist, SR 141716, on food intake and body weight gain of obese (fa/fa) compared to lean Zucker rats. Psychopharmacology (Berl) 2003;167:103-111.
13. Engeli S, Bohnke J, Feldpausch M et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes 2005;54:2838-2843.
14. Ravinet TC, Arnone M, Delgorge C et al. Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am J Physiol Regul Integr Comp Physiol 2003;284:R345-R353.
15. Bensaid M, Gary-Bobo M, Esclangon A et al. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol 2003;63:908-914.
16. Lofgren P, Sjolin E, Wahlen K, Hoffstedt J. Human adipose tissue cannabinoid receptor 1 gene expression is not related to fat cell function or adiponectin level. J Clin Endocrinol Metab 2007;92:1555-1559.